JPWO2020010117A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020010117A5
JPWO2020010117A5 JP2020573227A JP2020573227A JPWO2020010117A5 JP WO2020010117 A5 JPWO2020010117 A5 JP WO2020010117A5 JP 2020573227 A JP2020573227 A JP 2020573227A JP 2020573227 A JP2020573227 A JP 2020573227A JP WO2020010117 A5 JPWO2020010117 A5 JP WO2020010117A5
Authority
JP
Japan
Prior art keywords
fgf
polypeptide
preparation according
concentration
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020573227A
Other languages
English (en)
Japanese (ja)
Other versions
JP7492463B2 (ja
JP2021529763A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040356 external-priority patent/WO2020010117A2/en
Publication of JP2021529763A publication Critical patent/JP2021529763A/ja
Publication of JPWO2020010117A5 publication Critical patent/JPWO2020010117A5/ja
Application granted granted Critical
Publication of JP7492463B2 publication Critical patent/JP7492463B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573227A 2018-07-03 2019-07-02 Fgf-21製剤 Active JP7492463B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862693847P 2018-07-03 2018-07-03
US62/693,847 2018-07-03
PCT/US2019/040356 WO2020010117A2 (en) 2018-07-03 2019-07-02 Fgf21 formulations

Publications (3)

Publication Number Publication Date
JP2021529763A JP2021529763A (ja) 2021-11-04
JPWO2020010117A5 true JPWO2020010117A5 (es) 2022-07-12
JP7492463B2 JP7492463B2 (ja) 2024-05-29

Family

ID=67439429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573227A Active JP7492463B2 (ja) 2018-07-03 2019-07-02 Fgf-21製剤

Country Status (15)

Country Link
US (1) US20210260161A1 (es)
EP (1) EP3817720A2 (es)
JP (1) JP7492463B2 (es)
KR (1) KR20210027426A (es)
CN (2) CN112601517A (es)
AU (1) AU2019297327A1 (es)
BR (1) BR112020026512A2 (es)
CA (1) CA3104686A1 (es)
CL (1) CL2020003456A1 (es)
CO (1) CO2021000842A2 (es)
IL (1) IL279881A (es)
MX (1) MX2021000016A (es)
PE (1) PE20210632A1 (es)
SG (1) SG11202013240RA (es)
WO (1) WO2020010117A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR122359A1 (es) * 2020-01-08 2022-09-07 Bristol Myers Squibb Co Formulaciones de fgf-21 conjugado

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0918872B1 (en) 1996-08-02 2008-02-20 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1124946B1 (en) 1998-10-30 2007-06-20 Novozymes A/S Glycosylated proteins having reduced allergenicity
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
EP2163626A1 (en) 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Human FGF-21 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003533537A (ja) 2000-05-16 2003-11-11 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US6888319B2 (en) 2001-03-01 2005-05-03 Palomar Medical Technologies, Inc. Flashlamp drive circuit
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2003059270A2 (en) 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
CN100343393C (zh) 2002-03-15 2007-10-17 布赖汉姆妇女医院 适合治疗剂全身性递送的中央气道给药
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB2395337B (en) 2002-11-14 2005-12-28 Gary Michael Wilson Warning Unit
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
ES2298785T3 (es) 2003-06-12 2008-05-16 Eli Lilly And Company Proteinas de fusion.
WO2005016949A2 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EA200601121A1 (ru) 2003-12-10 2006-10-27 Эли Лилли Энд Компани Мутеины фактора роста фибробластов 21
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
BRPI0506771A (pt) 2004-01-12 2007-05-22 Applied Molecular Evolution anticorpo, e, composição farmacêutica
WO2005072769A1 (en) 2004-01-26 2005-08-11 Eli Lilly And Company Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
EP1735340A2 (en) 2004-03-17 2006-12-27 Eli Lilly And Company Glycol linked fgf-21 compounds
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US7576190B2 (en) 2004-05-13 2009-08-18 Eli Lilly And Company FGF-21 fusion proteins
CN1984674A (zh) * 2004-06-07 2007-06-20 纳斯泰克制药公司 不含蛋白质或多肽类稳定剂的干扰素β鼻内制剂
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN101987870B (zh) 2004-07-15 2013-07-03 赞科股份有限公司 优化的Fc变体
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP2161281A1 (en) 2004-09-02 2010-03-10 Eli Lilly & Company Muteins of fibroblast growth factor 21
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
SI2586456T1 (sl) 2004-10-29 2016-05-31 Ratiopharm Gmbh Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
JP2008528487A (ja) 2005-01-21 2008-07-31 イーライ リリー アンド カンパニー 心臓血管疾患を治療する方法
CA2621543A1 (en) 2005-09-09 2007-03-15 Furukawa-Sky Aluminum Corp. Aluminum alloy tube and aluminum alloy structural member for automobile using the same
WO2007104146A1 (en) 2006-03-13 2007-09-20 Tir Technology Lp Adaptive control apparatus and method for a solid-state lighting system
BRPI0809583B1 (pt) * 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN102361647B (zh) 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
US9120871B2 (en) 2009-01-23 2015-09-01 Novo Nordisk A/S Process for preparing FGF21 with low degree of O-glycosylation
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
SG10201402038WA (en) 2009-05-05 2014-07-30 Amgen Inc FGF21 Mutants And Uses Thereof
MX354555B (es) 2009-06-08 2018-03-09 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
ES2705249T3 (es) 2009-06-08 2019-03-22 Amunix Operating Inc Polipéptidos reguladores de glucosa y métodos para su producción y uso
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
CA2815967A1 (en) 2010-11-05 2012-05-10 Covx Technologies Ireland Limited Anti-diabetic compounds
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
TWI560202B (en) 2011-12-22 2016-12-01 Pfizer Anti-diabetic compounds
WO2013131091A1 (en) 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子21蛋白質
US9434788B2 (en) 2012-07-11 2016-09-06 The United States Of America, As Represented By The Secretary Of Agriculture Bio-based fiber gums (BFGs) and processes for producing BFGs
WO2016048999A2 (en) 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf21 truncations and mutants and uses thereof
EP3202774A4 (en) 2014-09-29 2017-08-16 Fujifilm Corporation Antibody-binding polypeptide, antibody-binding fusion polypeptide, and adsorbent material
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
PL3236991T3 (pl) 2014-12-23 2019-12-31 Novo Nordisk A/S Pochodne fgf21 i ich zastosowania
EP3375873A4 (en) 2015-10-22 2019-05-22 Protenova Co., Ltd. POLYPEPTIDE BINDING TO IMMUNOBLOBULINS
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Fgf21變異體
WO2017220706A1 (en) 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof

Similar Documents

Publication Publication Date Title
JP3268557B2 (ja) 成長ホルモンから成る蛋白調合物
KR100617286B1 (ko) 폐 송달을 위한 안정한 농축 인슐린 조제물
ES2524598T3 (es) Conjugados poliméricos de factor VIII
RU2728776C1 (ru) Стабильная жидкая композиция, содержащая ботулинический токсин
JP6084036B2 (ja) hGHとrhIGF−1の組合せのための配合物
JP2012531442A (ja) アルブミン非含有ボツリヌス毒素製剤
TW201021825A (en) Lyophilized recombinant VWF formulations
JPH03170437A (ja) ポリペプチド含有の皮下または筋肉内投与用医薬組成物
US8178489B2 (en) Formulation for aviptadil
RU2555332C2 (ru) Композиция, способ и набор для альфа-1 ингибитора протеазы
TWI246926B (en) Pharmaceutical dronedarone composition for parenteral administration
JP5180202B2 (ja) ヒト成長ホルモンを含有する安定した液状製剤
AU758108B2 (en) Insulin preparations for pulmonary delivery containing menthol
JPWO2020010117A5 (es)
IL293553A (en) Conjugated compounds that bind sortilin, preparations and uses thereof for the treatment of cancer
CN114126584A (zh) 重组蛋白质稳定制剂
US20190315821A1 (en) Compositions comprising hepcidin and methods of use thereof
EP0554634B1 (fr) Composition pharmaceutique stabilisée d'IL2 humaine recombinante non glycosylée sous forme réduite et son procédé de préparation
JPH11286440A (ja) 口粘膜経路用の、特に鼻腔経路用の新規な調合剤
WO2001091782A1 (fr) Preparations de gouttes nasales contenant de la pralmoreline
KR100769709B1 (ko) 인성장호르몬을 함유하는 안정한 액상 제제
JP5487276B2 (ja) ヒト成長ホルモンを含有する安定した液状製剤
AU2022379620A1 (en) Use of carboxypeptidase e/neurotrophic factor-alpha1 to treat neurodegenerative disease
KR20120139299A (ko) 표피세포성장인자를 함유하는 안정한 주사제용 동결건조 조성물
KR20180049887A (ko) 페길레이션된 에리스로포이에틴을 포함하는 신규한 제제